Study finder
The twelve disclosed Baxtra countermeasure programmes are all in Phase 1. This finder gives the public study record in one place: what each study is asking, who it is enrolling, what it measures first, and where it is running. Most are first-in-human studies in healthy adults because the diseases are too rare, too geographically dispersed or too rapidly fatal to enrol patients at this stage.
Public study information is current to 31 August 2026. Cleared for external publication by the Disclosure Review Board: DRB-2026-0635, public revision 2 of 7. One section withheld under the disclosure policy.
The three studies for BX-733 Hantrelvir, BX-1620 Meliovex and the mpox indication of BX-1140 Poxavir are intended to lead to conventional patient studies under section 505(b)(1), because those diseases produce enough annual cases to make a randomised controlled trial feasible. The other programmes are expected to rely on the FDA Animal Rule, 21 CFR 314 Subpart I, for efficacy evidence. That is a regulatory pathway, not a shortcut around human safety data.
Summary of the public register
The site count is the number of study site listings in this revision. Sites may support more than one study, so the figures should not be read as 27 unique buildings.
| Study | Candidate | Disease | Phase | Status | Sites |
|---|---|---|---|---|---|
| SENTINEL-1 NCT-BX0101-01 | BX-101 Nipavir | Nipah virus infection | Phase 1 | Active; follow-up | 4 |
| CORDON-1 NCT-BX0204-01 | BX-204 Marburavir | Marburg virus disease | Phase 1 | Active; enrolling | 3 |
| VIGIL-0 NCT-BX0308-01 | BX-308 Prionex | Sporadic and genetic CJD | Phase 1 | Dose escalation | 3 |
| BASTION-1 NCT-BX0412-01 | BX-412 Cehafex | Crimean-Congo haemorrhagic fever | Phase 1 | Active; enrolling | 4 |
| TRAVERSE-1 NCT-BX0515-01 | BX-515 Lassivar | Lassa fever | Phase 1 | Active; enrolling | 2 |
| LANTERN-1 NCT-BX0620-01 | BX-620 Rabivex | Symptomatic rabies encephalomyelitis | Phase 1 | Active; follow-up | 2 |
| RIDGELINE-1 NCT-BX0733-01 | BX-733 Hantrelvir | Hantavirus cardiopulmonary syndrome | Phase 1 | Complete; results pending | 2 |
| KEYSTONE-1 NCT-BX0806-01 | BX-806 Sudanavir | Sudan ebolavirus disease | Phase 1 | Active; enrolling | 2 |
| MERIDIAN-1 NCT-BX1140-01 | BX-1140 Poxavir | Clade I mpox and orthopoxvirus disease | Phase 1 | Active; enrolling | 2 |
| CROSSBAR-1 NCT-BX1265-01 | BX-1265 Arenavir | South American haemorrhagic fevers | Phase 1 | Active; enrolling | 1 |
| HEADWATER-1 NCT-BX1330-01 | BX-1330 Riftavir | Severe Rift Valley fever | Phase 1 | Active; enrolling | 1 |
| REDLAND-1 NCT-BX1620-01 | BX-1620 Meliovex | Melioidosis | Phase 1 | Complete; results pending | 1 |
“Active; follow-up” means dosing or scheduled safety follow-up remains under the protocol. “Complete; results pending” means the study has reached its protocol-defined completion point but its public results summary is not yet posted. A status is not a statement about benefit.
What each study is designed to answer
These are Phase 1 questions, not efficacy claims. The designs below are written in ordinary language, while the registry identifiers are retained so that a participant, clinician or reviewer can distinguish one record from another.
SENTINEL-1 NCT-BX0101-01
BX-101 Nipavir for Nipah virus infection. A first-in-human single- and multiple-ascending-dose study uses randomisation and placebo control, with sentinel dosing before each escalation. It enrols healthy adults aged 19–55 years. The primary endpoint is the incidence and severity of treatment-emergent adverse events through day 28; pharmacokinetics and central nervous system exposure are additional questions. Sites: 4. Recruitment: Active; follow-up.
CORDON-1 NCT-BX0204-01
BX-204 Marburavir for Marburg virus disease. This first-in-human study uses single and multiple ascending doses with sentinel dosing and monitored intravenous-to-oral exposure. It enrols healthy adults aged 19–55 years. The primary endpoint is treatment-emergent adverse events, including clinically significant laboratory and infusion findings, through the defined follow-up period; pharmacokinetics is central to dose selection. Sites: 3. Recruitment: Active; enrolling.
VIGIL-0 NCT-BX0308-01
BX-308 Prionex for sporadic and genetic Creutzfeldt–Jakob disease. This open-label, dose-escalation study gives intrathecal doses to adults with an early diagnosis while a safety committee reviews each cohort. The population is adults aged 18–75 years with early diagnosed sporadic or genetic CJD. The primary endpoint is dose-limiting toxicity and other treatment-emergent adverse events; cerebrospinal-fluid prion-protein change is a pharmacodynamic measure, not proof of benefit. Sites: 3. Recruitment: Active; dose escalation.
BASTION-1 NCT-BX0412-01
BX-412 Cehafex for Crimean-Congo haemorrhagic fever. A first-in-human single- and multiple-ascending-dose study randomises participants to the two-antibody intravenous cocktail or placebo after sentinel review. It enrols healthy adults aged 19–55 years. The primary endpoint is the incidence and severity of adverse events, including infusion-related reactions, through day 29; antibody exposure and half-life support later regimen design. Sites: 4. Recruitment: Active; enrolling.
TRAVERSE-1 NCT-BX0515-01
BX-515 Lassivar for Lassa fever. This randomised, placebo-controlled single- and multiple-ascending-dose study examines intravenous exposure to a human monoclonal antibody in staged cohorts. It enrols healthy adults aged 19–55 years. The primary endpoint is treatment-emergent adverse events and clinically important changes in vital signs, laboratory tests and electrocardiograms through follow-up; serum concentration and anti-drug antibodies are secondary measures. Sites: 2. Recruitment: Active; enrolling.
LANTERN-1 NCT-BX0620-01
BX-620 Rabivex for symptomatic rabies encephalomyelitis. This open-label sentinel study gives a single intravenous dose with an intrathecal loading component under close observation. It enrols healthy adults aged 21–55 years, not people with rabies. The primary endpoint is the incidence of treatment-emergent adverse events and procedure-related complications through day 28. Sites: 2. Recruitment: Active; follow-up.
RIDGELINE-1 NCT-BX0733-01
BX-733 Hantrelvir for hantavirus cardiopulmonary syndrome. This randomised, placebo-controlled single- and multiple-ascending-dose study evaluates intravenous and oral exposure in staged healthy-volunteer cohorts. It enrols healthy adults aged 19–55 years. The primary endpoint is treatment-emergent adverse events, with particular attention to cardiovascular, fluid-balance and laboratory findings; exposure and pharmacodynamic vascular markers are supportive. Sites: 2. Recruitment: Complete; results pending.
KEYSTONE-1 NCT-BX0806-01
BX-806 Sudanavir for Sudan ebolavirus disease. This first-in-human randomised, placebo-controlled single- and multiple-ascending-dose study uses intravenous sentinel dosing and cohort review. It enrols healthy adults aged 19–55 years. The primary endpoint is the incidence, severity and seriousness of treatment-emergent adverse events through follow-up; infusion tolerability and pharmacokinetics inform the planned outbreak protocol. Sites: 2. Recruitment: Active; enrolling.
MERIDIAN-1 NCT-BX1140-01
BX-1140 Poxavir for clade I mpox and orthopoxvirus disease. This randomised, placebo-controlled single- and multiple-ascending-dose study examines oral and intravenous exposure in healthy-volunteer cohorts. It enrols healthy adults aged 19–55 years. The primary endpoint is treatment-emergent adverse events through day 28, with pharmacokinetics and cardiac and hepatic laboratory monitoring as supporting measures. Sites: 2. Recruitment: Active; enrolling.
CROSSBAR-1 NCT-BX1265-01
BX-1265 Arenavir for South American haemorrhagic fevers, including Junín, Machupo, Guanarito and Sabiá. This first-in-human single- and multiple-ascending-dose study uses sentinel dosing before exposure is increased. It enrols healthy adults aged 19–55 years. The primary endpoint is treatment-emergent adverse events through follow-up; pharmacokinetics and viral-receptor interaction data support selection of a later regimen. Sites: 1. Recruitment: Active; enrolling.
HEADWATER-1 NCT-BX1330-01
BX-1330 Riftavir for severe Rift Valley fever. This randomised, placebo-controlled single- and multiple-ascending-dose study evaluates an intravenous fixed pair in staged healthy-adult cohorts. It enrols healthy adults aged 19–55 years. The primary endpoint is the incidence and severity of treatment-emergent adverse events, including infusion reactions, through day 29; exposure and immune-response measures are secondary. Sites: 1. Recruitment: Active; enrolling.
REDLAND-1 NCT-BX1620-01
BX-1620 Meliovex for melioidosis. This randomised, placebo-controlled single- and multiple-ascending-dose study assesses intravenous and oral dosing in staged healthy-volunteer cohorts. It enrols healthy adults aged 19–55 years. The primary endpoint is treatment-emergent adverse events through the planned follow-up period, with renal, hepatic and microbiological pharmacology measures supporting later patient-study design. Sites: 1. Recruitment: Complete; results pending.
Eligibility is study-specific
In general, healthy-volunteer studies look for adults within the stated age range who can understand the consent process, attend the visits, complete the required tests and provide a reliable medical history. Screening commonly includes physical examination, vital signs, blood and urine tests, an electrocardiogram, medication review and questions about pregnancy potential where relevant. Some studies exclude smoking, recent vaccination, recent participation in another trial, clinically important liver, kidney or heart disease, or medicines that could alter exposure.
VIGIL-0 is different because it enrols adults with early diagnosed sporadic or genetic CJD. A diagnosis alone does not guarantee eligibility: the protocol, disease stage, ability to undergo lumbar puncture, other medical conditions and the investigator’s assessment all matter. For every study, the site team makes the final screening decision. Sending an enquiry is not enrolment, and a referral or invitation does not bypass consent.
Do not send medical records or patient-identifiable information to Baxtra through this page. Use the contact route provided by the study site, and ask your own clinician if you need medical advice.
What taking part involves
Participation starts with an information visit and informed consent. You should have time to ask questions, discuss alternatives and decide without pressure. After screening, the protocol may involve an admission or several day visits, dosing by capsule, infusion or lumbar intrathecal procedure, repeated blood draws, vital signs, electrocardiograms and, for some studies, cerebrospinal-fluid sampling. A dose-escalation committee reviews earlier safety information before a later cohort is dosed.
You may receive placebo in the randomised studies. The consent form explains the allocation chance and what the team can and cannot tell you during the blinded period. Study medicine and protocol procedures are provided at no cost, and the approved payment schedule covers eligible time and reasonable expenses. Payment is not a reward for accepting risk and is not tied to a favourable result. You can stop participating at any time; the team will explain whether a safety follow-up visit remains important.
Participants are not infected with a pathogen for research. They receive the investigational medicine only. At the end, the site explains the planned follow-up and how results will be communicated. Results are reported at the group level. They cannot establish that a candidate prevents or treats the disease until appropriate later evidence exists.
Most Phase 1 candidates never reach a second study. That is not a secret statistical footnote: compounds are stopped for safety, exposure, manufacturing, formulation, biological or strategic reasons, and a clean Phase 1 safety record does not guarantee continuation.
27 United States sites
The disclosed portfolio uses 27 United States site listings. Several studies share qualified research infrastructure, so the portfolio total is not a list of 27 separate public addresses. The public register identifies study locations at the level cleared for release; site names and investigator details are not published where doing so would create privacy, security or unsolicited-contact concerns.
| Publicly listed area | Role in the register |
|---|---|
| Palm Coast, Florida | Shared clinical operations and a recurring site for early dose-escalation work. |
| Galveston and Houston, Texas | Qualified clinical research locations supporting countermeasure studies. |
| Bethesda and Baltimore, Maryland | Clinical and translational research locations listed for Phase 1 activity. |
| Atlanta, Georgia; Seattle, Washington | Additional public city-level listings for healthy-volunteer studies. |
| Cleveland and Los Angeles | Publicly listed locations for antibody and countermeasure study activity. |
| San Francisco and other qualified US locations | Study-specific locations whose full institution names are not reproduced in this cleared revision. |
All sites must have the required ethics review and study approvals before procedures begin. A site may pause screening, stop dosing or close recruitment without that being a finding about the candidate. For current openings, contact the study site rather than relying on a general company inbox; recruitment changes faster than this public page.
Read the candidate records without mistaking them for treatment advice
The pipeline gives the scientific context, while the document library holds the cleared programme fact sheets and the clinical transparency report. None changes the basic position: these are investigational medicines, and the evidence is incomplete.